C Esmon1. 1. Oklahoma Medical Research Foundation, Oklahoma City 73104, USA. charles-esmon@omrf.ouhsc.edu
Abstract
OBJECTIVE: To examine the role of the protein C anticoagulant pathway in the regulation of microvascular thrombosis. The mechanisms by which inflammation impairs the function of this pathway are also reviewed; conversely, we will survey emerging knowledge of the multiple mechanisms by which the protein C anticoagulant pathway can control the inflammatory response. DATA SOURCES: The information reviewed here was taken from the primary literature, including recent abstracts. STUDY SELECTION: All studies that bear directly on the interrelationship between the protein C anticoagulant pathway and inflammation were included, as was a summary of the initial clinical experience with protein C/activated protein C therapy in sepsis. DATA EXTRACTION AND SYNTHESIS: The results from each of the experimental approaches are summarized. Clinical experience with protein C supplementation in sepsis, although promising, is still in the early stages of study. CONCLUSIONS: The protein C anticoagulant pathway is a major mechanism in controlling microvascular thrombosis. Protein C deficiency that can occur in sepsis facilitates thrombin generation in the microvasculature, probably augmenting inflammatory responses and contributing to endothelial cell dysfunction. Animal studies and preliminary clinical results suggest that protein C/activated protein C supplementation may be useful in reversing microvascular dysfunction.
OBJECTIVE: To examine the role of the protein C anticoagulant pathway in the regulation of microvascular thrombosis. The mechanisms by which inflammation impairs the function of this pathway are also reviewed; conversely, we will survey emerging knowledge of the multiple mechanisms by which the protein C anticoagulant pathway can control the inflammatory response. DATA SOURCES: The information reviewed here was taken from the primary literature, including recent abstracts. STUDY SELECTION: All studies that bear directly on the interrelationship between the protein C anticoagulant pathway and inflammation were included, as was a summary of the initial clinical experience with protein C/activated protein C therapy in sepsis. DATA EXTRACTION AND SYNTHESIS: The results from each of the experimental approaches are summarized. Clinical experience with protein C supplementation in sepsis, although promising, is still in the early stages of study. CONCLUSIONS: The protein C anticoagulant pathway is a major mechanism in controlling microvascular thrombosis. Protein C deficiency that can occur in sepsis facilitates thrombin generation in the microvasculature, probably augmenting inflammatory responses and contributing to endothelial cell dysfunction. Animal studies and preliminary clinical results suggest that protein C/activated protein C supplementation may be useful in reversing microvascular dysfunction.
Authors: Myung S Park; Wenjun Z Martini; Michael A Dubick; Jose Salinas; Saulius Butenas; Bijan S Kheirabadi; Anthony E Pusateri; Jeffrey A Vos; Charles H Guymon; Steven E Wolf; Kenneth G Mann; John B Holcomb Journal: J Trauma Date: 2009-08
Authors: Christopher A Moxon; Samuel C Wassmer; Danny A Milner; Ngawina V Chisala; Terrie E Taylor; Karl B Seydel; Malcolm E Molyneux; Brian Faragher; Charles T Esmon; Colin Downey; Cheng-Hock Toh; Alister G Craig; Robert S Heyderman Journal: Blood Date: 2013-06-05 Impact factor: 22.113
Authors: François Fourrier; Francis Leclerc; Karl Aidan; Ahmed Sadik; Mercé Jourdain; Antoine Tournoys; Odile Noizet Journal: Intensive Care Med Date: 2003-05-22 Impact factor: 17.440
Authors: Madeline Betancourt; Peggy S McKinnon; R Michael Massanari; Salmaan Kanji; David Bach; John W Devlin Journal: Pharmacoeconomics Date: 2003 Impact factor: 4.981
Authors: Anne-Cornélie J M de Pont; Kamran Bakhtiari; Barbara A Hutten; Evert de Jonge; Margreeth B Vroom; Joost C M Meijers; Harry R Büller; Marcel Levi Journal: Crit Care Date: 2005-07-21 Impact factor: 9.097
Authors: Tiago D Martins; Joyce M Annichino-Bizzacchi; Anna V C Romano; Rubens Maciel Filho Journal: Clin Appl Thromb Hemost Date: 2019 Jan-Dec Impact factor: 2.389